We are live on ! Find out more
JAZZ icon

Jazz Pharmaceuticals

406 hedge funds and large institutions have $5B invested in Jazz Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 47 funds opening new positions, 123 increasing their positions, 171 reducing their positions, and 85 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.74% less ownership

Funds ownership: 91.96% → 89.22% (-2.7%)

9% less funds holding

Funds holding: 445 → 406 (-39)

20% less funds holding in top 10

Funds holding in top 10: 5 → 4 (-1)

28% less repeat investments, than reductions

Existing positions increased: 123 | Existing positions reduced: 171

33% less call options, than puts

Call options by funds: $18.3M | Put options by funds: $27.2M

39% less capital inflows, than outflows

Capital inflows: $478M | Capital outflows: $777M

45% less first-time investments, than exits

New positions opened: 47 | Existing positions closed: 85

Holders
406
Holders Change
-39
Holders Change %
-8.76%
% of All Funds
8.92%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.09%
New
47
Increased
123
Reduced
171
Closed
85
Calls
$18.3​M
Puts
$27.2​M
Net Calls
-⁠$8.94​M
Net Calls Change
-⁠$2.8​M

JAZZ Hedge Fund Activity: Q1 2020 in Review

406 of the 4,552 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q1 2020, worth a combined $5B — down 36% from $7.76B a quarter earlier.

Sellers outnumbered buyers: 85 funds closed out of JAZZ and 47 opened new positions — a net loss of 38 holders — while 171 trimmed existing stakes and 123 added.

The largest buyer was T. Rowe Price Associates, adding an estimated $65.2M. The largest seller was Arrowstreet Capital, cutting an estimated $57.9M.

  • 406 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q1 2020, down from 445 in Q4 2019.
  • Funds reported $5B of Jazz Pharmaceuticals stock for Q1 2020, down 36% quarter-over-quarter.
  • 47 funds opened new Jazz Pharmaceuticals positions in Q1 2020 and 85 closed out, a net change of -38 holders.
  • The largest Jazz Pharmaceuticals buyer in Q1 2020 was T. Rowe Price Associates, an estimated $65.2M added.
  • The largest Jazz Pharmaceuticals seller in Q1 2020 was Arrowstreet Capital, an estimated $57.9M sold.

Based on aggregated 13F filings for Q1 2020.